TEM on Nasdaq
Tempus AI
Logo: Tempus AI, Public domain, via Wikimedia Commons4
American health technology company
Tempus AI, Inc. (formerly Tempus Labs) is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Outbrain, Kanzhun Ltd or Bumble, or pick any stock.
- TickerTEM on Nasdaq1
- IndustryServices-Computer Programming, Data Processing, Etc.1
- HeadquartersChicago1
- Websitewww.tempus.com
- Incorporated inNV6
- Business address600 West Chicago Avenue, Suite 510, Chicago, Il 606546
- Filer categoryLarge accelerated filer6
See how the biggest companies compare on our leaderboards
Tempus AI, Inc. (formerly Tempus Labs) is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Diagnostics brought in 75% of the revenue Tempus AI broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Diagnostics | $363.0M | $451.7M | $955.4M |
| Insights Product | $117.6M | $186.8M | $257.7M |
| Trials Product | $45.6M | $42.4M | $38.5M |
| AI Applications | $5.1M | $12.3M | $20.1M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development14¢$172.9M
- Selling, general and admin58¢$731.7M
- Other costs25¢$315.4M
- Income tax4¢$51.7M
Out of $1.3B in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 4 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total net revenue | $1.3B | $693.4M | $531.8M | |
| Technology research and development | $146.1M | $167.5M | $95.2M | |
| Research and development | $172.9M | $149.3M | $90.3M | |
| Selling, general and administrative | $731.7M | $755.4M | $296.8M | |
| Total cost and operating expenses | $1.5B | $1.4B | $727.9M | |
| Loss from operations | -$252.9M | -$691.1M | -$196.1M | |
| Interest income | $12.6M | $11.1M | $7.6M | |
| Interest expense | -$70.3M | -$53.7M | -$46.9M | |
| Loss on debt extinguishment | -$12.0M | $0 | $0 | |
| Other income, net | $31.4M | $32.3M | $21.8M | |
| Loss before benefit from (provision for) income taxes | -$291.1M | -$701.3M | -$213.5M | |
| benefit from (Provision for) income taxes | $51.7M | -$266.0K | -$288.0K | |
| losses from equity method investments | -$5.6M | -$4.2M | -$301.0K | |
| Net Loss | -$245.0M | -$705.8M | -$214.1M | |
| Accretion of convertible preferred stock to redemption value | $0 | $0 | -$4.3M | |
| Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares | $0 | -$39.3M | -$44.5M | |
| Cumulative undeclared dividends on Series C preferred shares | $0 | -$1.2M | -$3.0M | |
| Net loss attributable to common shareholders, basic | -$245.0M | -$746.3M | -$266.0M | |
| Net loss attributable to common shareholders, diluted | -$245.0M | -$746.3M | -$266.0M | |
| Net loss per share attributable to common shareholders, basic | -$1.41 | -$6.23 | -$4.20 | |
| Net loss per share attributable to common shareholders, diluted | -$1.41 | -$6.23 | -$4.20 | |
| Weighted-average shares outstanding used to compute net loss per share, basic | 174.3K shares | 119.8K shares | 63.3K shares | 63.3K shares |
| Weighted-average shares outstanding used to compute net loss per share, diluted | 174.3K shares | 119.8K shares | 63.3K shares | |
| Foreign currency translation adjustment | $808.0K | $89.0K | -$13.0K | |
| Comprehensive loss | -$244.2M | -$705.7M | -$214.1M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $604.8M | $341.0M | $165.8M | |
| Accounts receivable, net of allowances of $2,755 and $1,141 at December 31, 2025 and 2024, respectively | $311.2M | $154.8M | ||
| Inventory | $51.7M | $38.4M | ||
| Related party asset | $8.8M | |||
| Prepaid expenses and other current assets | $40.5M | $26.1M | ||
| Marketable equity securities | $150.2M | $107.3M | ||
| Total current assets | $1.2B | $667.6M | ||
| Property and equipment, net | $89.2M | $58.1M | ||
| Goodwill | $470.2M | $73.3M | $73.4M | |
| Intangible assets, net | $355.3M | $11.7M | ||
| Investments and other assets | $21.1M | $8.3M | ||
| Investment in joint venture | $86.6M | $91.5M | ||
| Related party asset, less current portion | $16.2M | |||
| Operating lease right-of-use assets | $64.5M | $14.8M | ||
| Restricted cash | $4.7M | $881.0K | ||
| Total Assets | $2.3B | $926.1M | ||
| Accounts payable | $82.0M | $53.8M | ||
| Accrued expenses | $155.4M | $130.4M | ||
| Deferred other income | $16.0M | $16.0M | ||
| Other current liabilities | $8.7M | $7.0M | ||
| Operating lease liabilities | $13.4M | $6.5M | ||
| Accrued data licensing fees | $4.4M | $1.5M | ||
| Total current liabilities | $372.4M | $291.1M | ||
| Operating lease liabilities, less current portion | $74.3M | $26.2M | ||
| Convertible promissory note | $208.7M | $168.2M | ||
| Other long-term liabilities | $56.6M | $16.0M | ||
| Revolving credit facility | $100.0M | |||
| Interest payable | $12.4M | $70.5M | ||
| Long-term debt, net | $202.8M | $267.2M | ||
| Convertible senior notes, net | $728.1M | |||
| Deferred other income, less current portion | $8.0M | $23.9M | ||
| Deferred revenue, less current portion | $20.4M | $6.7M | ||
| Total Liabilities | $1.8B | $869.8M | ||
| Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at December 31, 2025 and 2024, respectively, no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | ||
| Treasury Stock, 183,229 and 145,466 shares at December 31, 2025 and 2024, respectively, at cost | -$6.6M | -$3.6M | ||
| Additional Paid-In Capital | $2.9B | $2.2B | ||
| Accumulated Other Comprehensive Income | $902.0K | $94.0K | ||
| Accumulated deficit | -$2.4B | -$2.2B | ||
| Total Stockholders' equity | $491.3M | $56.3M | -$1.4B | -$1.1B |
| Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity | $2.3B | $926.1M | ||
| Accounts receivable, net of allowances | $2.8M | $1.1M | ||
| Related party deferred revenue | $92.7M | $76.0M | ||
| Treasury stock common shares | 183.2K shares | 145.5K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $604.8M | $341.0M | $165.8M | |
| Accounts receivable, net of allowances of $2,755 and $1,141 at December 31, 2025 and 2024, respectively | $311.2M | $154.8M | ||
| Inventory | $51.7M | $38.4M | ||
| Related party asset | $8.8M | |||
| Prepaid expenses and other current assets | $40.5M | $26.1M | ||
| Marketable equity securities | $150.2M | $107.3M | ||
| Total current assets | $1.2B | $667.6M | ||
| Property and equipment, net | $89.2M | $58.1M | ||
| Goodwill | $470.2M | $73.3M | $73.4M | |
| Intangible assets, net | $355.3M | $11.7M | ||
| Investments and other assets | $21.1M | $8.3M | ||
| Investment in joint venture | $86.6M | $91.5M | ||
| Related party asset, less current portion | $16.2M | |||
| Operating lease right-of-use assets | $64.5M | $14.8M | ||
| Restricted cash | $4.7M | $881.0K | ||
| Total Assets | $2.3B | $926.1M | ||
| Accounts payable | $82.0M | $53.8M | ||
| Accrued expenses | $155.4M | $130.4M | ||
| Deferred other income | $16.0M | $16.0M | ||
| Other current liabilities | $8.7M | $7.0M | ||
| Operating lease liabilities | $13.4M | $6.5M | ||
| Accrued data licensing fees | $4.4M | $1.5M | ||
| Total current liabilities | $372.4M | $291.1M | ||
| Operating lease liabilities, less current portion | $74.3M | $26.2M | ||
| Convertible promissory note | $208.7M | $168.2M | ||
| Other long-term liabilities | $56.6M | $16.0M | ||
| Revolving credit facility | $100.0M | |||
| Interest payable | $12.4M | $70.5M | ||
| Long-term debt, net | $202.8M | $267.2M | ||
| Convertible senior notes, net | $728.1M | |||
| Deferred other income, less current portion | $8.0M | $23.9M | ||
| Deferred revenue, less current portion | $20.4M | $6.7M | ||
| Total Liabilities | $1.8B | $869.8M | ||
| Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at December 31, 2025 and 2024, respectively, no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | ||
| Treasury Stock, 183,229 and 145,466 shares at December 31, 2025 and 2024, respectively, at cost | -$6.6M | -$3.6M | ||
| Additional Paid-In Capital | $2.9B | $2.2B | ||
| Accumulated Other Comprehensive Income | $902.0K | $94.0K | ||
| Accumulated deficit | -$2.4B | -$2.2B | ||
| Total Stockholders' equity | $491.3M | $56.3M | -$1.4B | -$1.1B |
| Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity | $2.3B | $926.1M | ||
| Accounts receivable, net of allowances | $2.8M | $1.1M | ||
| Related party deferred revenue | $92.7M | $76.0M | ||
| Treasury stock common shares | 183.2K shares | 145.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$245.0M | -$705.8M | -$214.1M |
| Change in fair value of warrant liability | $0 | $42.4M | -$8.0M |
| Gain on warrant termination | $0 | -$39.1M | $0 |
| Reversal of warrant contract asset amortization | $0 | -$16.3M | $0 |
| Stock-based compensation | $124.7M | $534.1M | $0 |
| Gain on warrant exercise | $0 | -$173.0K | $0 |
| Gain on marketable equity securities | -$16.5M | -$12.1M | -$9.8M |
| Loss on disposal of property and equipment | $415.0K | $0 | $0 |
| Loss on debt extinguishment | $12.0M | $0 | $0 |
| Deferred income taxes | -$52.7M | $0 | $0 |
| Losses from equity method investments | $5.6M | $4.2M | $301.0K |
| Amortization of original issue discount | $4.1M | $1.4M | $1.1M |
| Amortization of deferred financing fees | $484.0K | $510.0K | $510.0K |
| Change in fair value of contingent consideration | $0 | $72.0K | -$400.0K |
| Change in fair value of holdback liability | -$1.3M | $0 | $0 |
| Amortization of warrant contract asset | $0 | $4.8M | $5.2M |
| Depreciation and amortization | $102.3M | $37.2M | $33.0M |
| Provision for bad debt expense | $2.6M | $680.0K | $1.6M |
| Provision for obsolete inventory | $1.3M | $0 | $0 |
| Amortization of finance right-of-use lease assets | $0 | $0 | $283.0K |
| Change in fair value of warrant asset | $0 | -$18.3M | -$4.1M |
| Non-cash operating lease costs | $11.6M | $6.0M | $6.8M |
| Minimum accretion expense | $268.0K | $197.0K | $90.0K |
| Impairment of intangible assets | $0 | $0 | $7.4M |
| PIK interest added to principal | $10.5M | $8.8M | $3.6M |
| Inventory | -$3.4M | -$9.5M | -$6.6M |
| Prepaid expenses and other current assets | -$1.7M | -$13.7M | -$6.5M |
| Investments and other assets | -$17.3M | -$751.0K | -$4.2M |
| Accounts payable | -$7.2M | -$23.9M | -$23.4M |
| Related party asset | -$25.0M | $0 | $0 |
| Deferred revenue | -$7.0M | -$20.9M | -$26.4M |
| Deferred other income | -$16.0M | $39.9M | $0 |
| Accrued data licensing fees | $3.0M | -$5.0M | -$9.1M |
| Accrued expenses & other | -$12.8M | $50.5M | $38.6M |
| Interest payable | $14.2M | $15.1M | $15.8M |
| Operating lease liabilities | -$14.9M | -$8.6M | -$8.8M |
| Net cash used in operating activities | -$218.1M | -$189.0M | -$214.3M |
| Purchases of property and equipment | -$21.0M | -$22.1M | -$34.6M |
| Proceeds from sale of marketable equity securities | $8.3M | $23.1M | $0 |
| Purchases of marketable equity securities | -$2.7M | -$36.2M | $0 |
| Business combinations, net of cash acquired | -$376.7M | $0 | -$5.7M |
| Investment in joint venture | $0 | -$95.2M | $0 |
| Capitalized software costs | -$6.2M | $0 | $0 |
| Net cash used in investing activities | -$398.4M | -$130.4M | -$40.3M |
| Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions | $0 | $382.0M | $0 |
| Tax withholding related to net share settlement of restricted stock units | $0 | -$69.9M | $0 |
| Issuance of Series G-4 Preferred Stock, net of offering costs | $0 | $0 | $44.9M |
| Issuance of Series G-5 Preferred Stock | $0 | $199.8M | $0 |
| Principal payments on finance lease liabilities | $0 | $0 | -$288.0K |
| Purchase of treasury stock | -$3.0M | $0 | -$3.6M |
| Payment of deferred offering costs | -$806.0K | -$8.8M | -$698.0K |
| Dividends paid | $0 | -$5.6M | -$5.6M |
| Proceeds from revolving credit facility, net of original issue discount | $98.0M | $0 | $0 |
| Proceeds from long-term debt, net of original issue discount | $196.0M | $0 | $82.9M |
| Proceeds from convertible senior notes, net of initial purchasers' discount | $726.5M | $0 | $0 |
| Payment of deferred financing fees | -$1.5M | $0 | $0 |
| Payment of indemnity holdback related to acquisition | $0 | -$813.0K | $0 |
| G-4 Special Payment | $0 | -$2.2M | $0 |
| Principal payments on long-term debt | -$276.9M | $0 | $0 |
| Prepayment premium on long-term debt | -$7.8M | $0 | $0 |
| Purchases of capped call | -$41.8M | $0 | $0 |
| Proceeds from issuance of common stock in connection with at-the-market offering, net of commissions | $195.5M | $0 | $0 |
| Net cash provided by financing activities | $884.1M | $494.3M | $117.5M |
| Effect of foreign exchange rates on cash | -$62.0K | $336.0K | -$19.0K |
| Net increase (decrease) in Cash, Cash Equivalents and Restricted Cash | $267.6M | $175.2M | -$137.1M |
| Cash paid during the year for interest | $44.0M | $28.0M | $16.9M |
| Cash paid for income taxes | $654.0K | $206.0K | $161.0K |
| Marketable equity securities received on accounts receivable | $32.0M | $22.0M | $22.0M |
| Dividends Payable | $0 | $5.5M | $12.5M |
| Purchases of property and equipment, accrued but not paid | $5.5M | $4.3M | $6.1M |
| Redemption of convertible promissory note | $32.0M | $24.9M | $28.0M |
| Non-voting common stock issued in connection with business combinations | $0 | $344.0K | $9.2M |
| Accretion of convertible preferred stock to redemption value | $0 | $0 | $4.3M |
| Deferred offering costs, accrued but not yet paid | $47.0K | $0 | $3.5M |
| Deferred financing fees, accrued but not yet paid | $226.0K | $0 | $0 |
| Reclassification of deferred offering costs to additional paid-in capital upon at-the-market offering | $821.0K | $0 | $0 |
| Operating lease liabilities arising from obtaining right-of-use assets | $22.7M | $2.0M | $1.1M |
| Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering | $0 | $1.3B | $0 |
| Taxes related to net share settlement of restricted stock units not yet paid | $0 | $20.0K | $0 |
| Reclassification of deferred offering costs to additional paid-in capital upon initial public offering | $0 | $12.3M | $0 |
| Class A Common Stock issued in connection with business combinations | $403.2M | $0 | $0 |
| Class A Common Stock issued in connection with license agreement | $1.4M | $0 | $0 |
| Issuance of warrant | $0 | $0 | $4.2M |
| Issuance of common stock in connection with contingent consideration | $0 | $847.0K | $0 |
| Convertible promissory note principal reset due to amendment | $72.5M | $0 | $0 |
| Increase in related party accounts receivable | $90.4M | $61.0M | $7.3M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Tempus AI, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief operating officer
- Chief executive officerRyan Fukushima Feb 20, 2026 to Feb 25, 202613
- Chief executive officerThomas Edward Schoenherr Feb 25, 2026 to now14
- Chief operating officerRyan Fukushima Jun 13, 2024 to now15
Board members and other officers (11)
- EVP & Chief Admin & Legal OffErik Phelps Jun 13, 2024 to now16
- Chief Accounting OfficerRyan M. Bartolucci Jun 17, 2024 to now17
- Board memberDavid R. Epstein Jun 13, 2024 to now18
- Board memberEric D. Belcher Jun 13, 2024 to now19
- Board memberJennifer Doudna Jun 13, 2024 to now20
- Board memberNadja West Jun 13, 2024 to now21
- Board memberPeter J. Barris Jun 13, 2024 to now22
- Board memberScott Gottlieb Jun 13, 2024 to now23
- Board memberTheodore Leonsis Jun 13, 2024 to now24
- Board memberWayne A.I. Frederick Jun 13, 2024 to now25
- General counselAndrew Polovin Jun 13, 2024 to now26
Products and brands
Tempus does genome sequencing and precision medicine, including diagnostics, primarily for cancer patients, as well as for cardiology patients, radiology, and pharmacogenomic testing for patients with depression. It is headquartered in Chicago.
Tempus investors include SoftBank Group, Baillie Gifford, New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution LLC, Google LLC, and others.
In June 2024, Tempus and SoftBank formed an AI healthcare joint venture in Japan called SB Tempus with a plan to develop personalized treatment recommendations by analyzing medical data with AI. In November that year, Tempus agreed to acquire California-based genetic testing company Ambry Genetics for $600 million in a cash-and-stock deal.
In July 2026, Tempus agreed to acquire cancer-testing company Personalis in a deal valued at approximately US$1.5 billion. The acquisition would add Personalis's NeXT Personal cancer test to Tempus's oncology portfolio and is expected to close in late 2026 or early 2027.
Read the full text
The company's advisory board includes Jennifer Doudna and Scott Gottlieb. At the end of 2025, Tempus employs around 3,800 people.
From Wikipedia’s article on Tempus AI, shared under CC BY-SA 4.0.7
Former names
- Tempus Labs, Inc.Sep 25, 2017 to Dec 5, 20236
Timeline
Filings
491 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 24 major events, 232 insider forms, 21 large holders, 1 private raises, 204 other. The latest 20:
- Oct 2, 2026S-4/A EDGAR
- Sep 29, 20264 EDGAR
- Sep 25, 2026144 EDGAR
- Sep 24, 20264 EDGAR
- Sep 22, 2026144 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 17, 2026144 EDGAR
- Sep 17, 2026144 EDGAR
- Sep 17, 2026144 EDGAR
- Sep 16, 2026144 EDGAR
- Sep 15, 2026425 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 1, 2026144 EDGAR
- Sep 1, 2026144 EDGAR
- Sep 1, 20264 EDGAR
The 491 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 21 such filings since October 2021, the latest 10:
- Jul 21, 2026SCHEDULE 13D/A
- May 7, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Mar 6, 2026SCHEDULE 13G
- Feb 10, 2026SCHEDULE 13G/A
- Nov 13, 2025SCHEDULE 13G/A
- Nov 12, 2025SCHEDULE 13G/A
- Oct 31, 2025SCHEDULE 13G
- Sep 12, 2025SCHEDULE 13D/A
- May 15, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Oct 3, 2022Raised $10 million in a private offering of equity Form D: 4 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| ARK Investment Management LLC | 10,022,634 | $580.6M | 3.8% | +414,889 |
| BlackRock, Inc. | 8,291,053 | $480.3M | 0.0% | −677,277 |
| Baillie Gifford & Co | 8,190,133 | $474.5M | 0.4% | −459,223 |
| Softbank Group Corp. | 5,405,406 | $313.1M | 1.7% | No change |
| Jpmorgan Chase & Co | 4,989,062 | $291.2M | 0.0% | +55,869 |
| Vanguard Capital Management LLC | 4,988,038 | $289.0M | 0.0% | +69,916 |
| Vanguard Portfolio Management LLC | 4,914,410 | $284.7M | 0.0% | +235,353 |
| Sumitomo Mitsui Trust Group, Inc. | 4,089,029 | $236.9M | 0.1% | −237,284 |
| Amova Asset Management Americas, Inc. | 4,089,029 | $236.6M | 3.1% | −237,284 |
| Goldman Sachs Group Inc | 3,761,666 | $217.9M | 0.0% | +2,483,910 |
| Morgan Stanley | 3,652,136 | $211.6M | 0.0% | +1,568,701 |
| Franklin Resources Inc | 3,352,768 | $194.2M | 0.0% | +771,124 |
| UBS Group AG | 2,546,634 | $147.5M | 0.0% | −687,753 |
| Citadel Advisors LLC | 2,512,401 | $145.5M | 0.1% | +1,911,096 |
| GC Wealth Management RIA, LLC | 2,411,368 | $139.7M | 8.1% | −4,199,843 |
| Geode Capital Management, LLC | 2,092,519 | $121.2M | 0.0% | +152,312 |
| Bank Of America Corp /de/ | 1,917,772 | $111.1M | 0.0% | +1,502,992 |
| State Street Corp | 1,887,599 | $109.3M | 0.0% | +197,838 |
| Alphabet Inc. | 1,551,102 | $89.9M | 0.1% | No change |
| Jane Street Group, LLC | 1,428,847 | $82.8M | 0.1% | +759,993 |
| Lingotto Investment Management LLP | 1,415,766 | $82.0M | 1.8% | No change |
| Clear Street Group Inc. | 1,345,069 | $77.9M | 0.2% | +389,487 |
| Legal & General Group Plc | 1,145,900 | $66.4M | 0.0% | +374,526 |
| Norges Bank | 975,302 | $56.5M | 0.0% | New |
| Bamco Inc /ny/ | 904,259 | $52.4M | 0.1% | +4,981 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Jan 14, 2025 | Nancy PelosiDemocratic, House | Buy | $50,001 - $100,000 | +95.6% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Links
- Websitewww.tempus.com1
- WikipediaTempus AI
- WikidataQ127040202
- SEC EDGARCIK 1717115
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataTempus AI on Wikidata
- 2SEC EDGARTempus AI filings on SEC EDGAR
- 3WikipediaTempus AI on Wikipedia
- 4Wikimedia CommonsTempus AI logo by Tempus AI, Public domain
- 5SEC EDGARTempus AI 10-K for fiscal 2025
- 6SEC EDGARTempus AI filings on SEC EDGAR
- 7
- 8SEC EDGARTempus AI 10-K for fiscal 2022
- 9SEC EDGARTempus AI 10-Q for fiscal 2025
- 10SEC EDGARTempus AI 10-Q for fiscal 2025
- 11SEC EDGARTempus AI 10-Q for fiscal 2026
- 12SEC EDGARTempus AI 10-Q for fiscal 2025
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARDavid R. Epstein, Board member
- 19SEC EDGAREric D. Belcher, Board member
- 20SEC EDGARJennifer Doudna, Board member
- 21SEC EDGARNadja West, Board member
- 22SEC EDGARPeter J. Barris, Board member
- 23SEC EDGARScott Gottlieb, Board member
- 24SEC EDGARTheodore Leonsis, Board member
- 25SEC EDGARWayne A.I. Frederick, Board member
- 26SEC EDGARAndrew Polovin, General counsel
- 27gleifTempus AI is founded